NextCure Inc.’s stock surges nearly 30% after promising preclinical data for its brittle bone disease treatment, NC605, highlights the company’s potential in addressing rare diseases.

NextCure Inc.’s stock price surged nearly 30% after the company released promising preclinical data for its brittle bone disease treatment, NC605.

NextCure Inc. has formed a strategic partnership with Simcere Zaiming to develop a novel antibody-drug conjugate (ADC) targeting CDH6, a promising cancer treatment, with a deal worth up to $745 million.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing immunomedicines for cancer and other diseases, with a market capitalization of $13.9 million.

NextCure, a clinical-stage biopharmaceutical company, showcased its commitment to innovation and cancer treatment at the 24th Annual Needham Virtual Healthcare Conference, despite navigating market volatility and financial challenges.